These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 23097775)
1. FDA approves Belviq to treat some overweight or obese adults. Home Healthc Nurse; 2012 Sep; 30(8):443-4. PubMed ID: 23097775 [No Abstract] [Full Text] [Related]
2. Clinical inquiries: is immediate-release topiramate an effective treatment for adult obesity? Harshman H; Kovach F J Fam Pract; 2014 Dec; 63(12):745-6. PubMed ID: 25486315 [No Abstract] [Full Text] [Related]
3. Drug management of obesity--efficacy versus safety. Astrup A N Engl J Med; 2010 Jul; 363(3):288-90. PubMed ID: 20647205 [No Abstract] [Full Text] [Related]
4. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Bays HE Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803 [TBL] [Abstract][Full Text] [Related]
5. The FDA's assessment of two drugs for chronic weight management. Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510 [No Abstract] [Full Text] [Related]
6. Diet drugs Belviq and Qsymia receive FDA approval: what dentists need to know. Wynn RL Gen Dent; 2013; 61(1):11-3. PubMed ID: 23302354 [No Abstract] [Full Text] [Related]
7. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen. Azebu LM Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687 [TBL] [Abstract][Full Text] [Related]
8. Multicenter, placebo-controlled trial of lorcaserin for weight management. Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR; N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200 [TBL] [Abstract][Full Text] [Related]
9. Two new drugs approved for obesity. Johnson AM S D Med; 2012 Sep; 65(9):356-7. PubMed ID: 23066610 [No Abstract] [Full Text] [Related]
10. Lorcaserin approval in the United States: paving the way? Pedersen SD; Astrup A Endocrinol Nutr; 2012 Nov; 59(9):521-2. PubMed ID: 22939712 [No Abstract] [Full Text] [Related]
11. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. Wang PW; Hill SJ; Childers ME; Chandler RA; Rasgon NL; Ketter TA J Psychiatr Res; 2011 Aug; 45(8):1128-32. PubMed ID: 21371718 [TBL] [Abstract][Full Text] [Related]
12. Lorcaserin for weight loss: insights into US Food and Drug Administration approval. Miller LE J Acad Nutr Diet; 2013 Jan; 113(1):25-30. PubMed ID: 23260720 [No Abstract] [Full Text] [Related]
16. Insurers find small gains in weight control with Belviq. Morrow T Manag Care; 2012 Aug; 21(8):45-6. PubMed ID: 22957469 [No Abstract] [Full Text] [Related]
17. The FDA approves new drug for smoking cessation. FDA Consum; 2006; 40(4):29. PubMed ID: 17243286 [TBL] [Abstract][Full Text] [Related]
18. Trial of lorcaserin for weight management. Jia J; Xiong L; Chen S N Engl J Med; 2010 Dec; 363(25):2468-9; author reply 2469-70. PubMed ID: 21158670 [No Abstract] [Full Text] [Related]
19. Secular trends in the diagnosis and treatment of obesity among US adults in the primary care setting. Yates EA; Macpherson AK; Kuk JL Obesity (Silver Spring); 2012 Sep; 20(9):1909-14. PubMed ID: 21869761 [TBL] [Abstract][Full Text] [Related]
20. FDA approves first canine diet drug. Nolen RS J Am Vet Med Assoc; 2007 Mar; 230(5):641-2. PubMed ID: 17380625 [No Abstract] [Full Text] [Related] [Next] [New Search]